Seres Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $789.0K | $0 | $0 | $7.1M | $144.9M | $33.2M | $34.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M | $90.6M | $80.1M |
| SG&A Expense | — | $39.2M | $53.2M | $77.5M | $70.3M | $69.3M | $30.8M | $24.7M |
| Operating Income | — | $-94.0M | $-121.3M | $-195.1M | $-179.9M | $-64.5M | $-88.1M | $-71.9M |
| Operating Margin | — | -11,910.1% | — | — | -2,524.0% | -44.5% | -265.3% | -208.3% |
| Interest Expense | — | $0 | $0 | $2.5M | $6.0M | $2.9M | $2.9M | $502.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $5.7M | $136.0K | $-113.7M | $-250.2M | $-65.6M | $-89.1M | $-70.3M |
| Net Margin | — | 721.9% | — | — | -3,509.5% | -45.2% | -268.3% | -203.7% |
| EPS (Basic) | — | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 | $-1.12 | $-1.24 |
| EPS (Diluted) | — | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 | $-1.12 | $-1.24 |
| Shares Outstanding (Basic) | 9.6M | 8.9M | 7.8M | 6.4M | 108.1M | 91.7M | 79.8M | 70.1M |
| Shares Outstanding (Diluted) | 9.6M | 8.9M | 7.8M | 6.4M | 108.1M | 91.7M | 79.8M | 70.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |